Antitrust is key against pharma monopolies---leads to lower healthcare costs, better healthcare quality, and better innovation.
FTC 23, an independent agency of the United States government whose principal mission is the enforcement of civil antitrust law and the promotion of consumer protection. (Federal Trade Commision, 12-7-2023, " FTC, DOJ and HHS Work to Lower Health Care and Drug Costs, Promote Competition to Benefit Patients, Health Care Workers," Source, accessed 7/29/2024, https://www.ftc.gov/news-events/news/press-releases/2023/12/ftc-doj-hhs-work-lower-health-care-drug-costs-promote-competition-benefit-patients-health-care) //CPSW_AChiong
Recent agency actions have helped lower costs, increase care quality for consumers and promote competition across the health care market
Anticompetitive acquisitions and practices can chill fair competition, leading to higher health care costs, degraded working conditions, and less innovation across the health care and pharmaceutical industries. Through regulatory and legal actions, the Federal Trade Commission (FTC), Department of Justice (DOJ), and Department of Health and Human Services (HHS) are each working to promote competition to lower health care costs for families and taxpayers and improve the quality and availability of health care for patients.